Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.
about
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseInhaled corticosteroids for stable chronic obstructive pulmonary diseaseInhaled corticosteroids for stable chronic obstructive pulmonary diseaseA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary diseaseCOPD exacerbations. 4: PreventionInhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updatePharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study.Inhibition of granulocyte migration by tiotropium bromideMarkers of exacerbation severity in chronic obstructive pulmonary diseaseEvaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary diseasePrimary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation studyImprovement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?Time course of recovery of health status following an infective exacerbation of chronic bronchitis.Inhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseSputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary diseaseMetabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease.Geographic variation in chronic obstructive pulmonary disease exacerbation ratesMinimal clinically important difference--exacerbations of COPD.Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease.The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPDPharmacological treatment of chronic obstructive pulmonary disease.Eosinophilic airway inflammation in COPDEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.One-year treatment with mometasone furoate in chronic obstructive pulmonary diseaseInhaled corticosteroids can reduce osteoporosis in female patients with COPDInhaled and systemic corticosteroids in chronic obstructive pulmonary disease.Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.The severity of airways obstruction as a determinant of treatment response in COPD.
P2860
Q24197853-E3925C77-1CBE-4508-8ECD-95F87714B318Q24197989-AEF1FB31-50E5-43CF-A902-4EABBBFC5525Q24202092-8AE3E1BA-5DBD-4B82-B690-71781C0FE8FBQ24245481-513F30A5-BAF5-4F27-8175-D4D9F7DF1062Q26801661-0E0B777E-987C-4626-A4BC-15BCA9278A1CQ27027955-8B130A29-DC5C-4E4E-9B70-786F8B0029DAQ27348844-77A01082-4E0E-4AFD-AAE3-923DD614713EQ28761895-C80B3E99-A506-487E-9455-4B5D8AAF10E1Q30480789-80552933-873C-49CA-944B-89B82C0E7F8DQ30654188-1035536E-51AB-4870-8316-F455FA55782EQ33591899-F5602CF0-56E8-4C14-A621-6EBDF93F3A51Q33706037-8348A957-D66B-4FDF-86E1-0564B651A37CQ33796149-3317578D-8523-4A8F-A482-D9B45CF0CC70Q34109192-269863AC-6D56-4912-A780-A25B782B6193Q34638204-C7C80324-0F53-43E8-ADC5-C3AA2AC76A34Q34691221-9BE10BF2-E2CF-4387-9A75-6BC51083E2E4Q35049724-4E334122-C810-4E62-A436-94152FE7E847Q35112110-0F4E94D2-A4B1-4C67-9010-D13177249C5FQ35119108-46D25E8E-6CA3-4FAE-B294-94E255C2EDEAQ35536058-6DA05630-CD3C-477E-8788-73B8CE83C35BQ35537366-FE47D961-3786-43A4-B1F5-EFA5DADFCDBDQ35537515-FD827FE9-6FB4-4039-8007-C2F2C209D617Q35537740-B3993689-7DE0-43FA-9936-1EFFA1764DFBQ35703517-16E0B36C-DB61-4122-85BA-3695EC988BAEQ35826070-683FF95A-7E65-4E18-B151-FA06CAC75191Q36141290-9EBEBDD6-4987-4A76-9629-DFE9D010CBF6Q36208427-5828D090-0DBB-4FD7-8DF7-2FB2E86BD434Q36388372-CEF3CF93-8BB0-4BD3-BE81-DE3657634B14Q36416859-D191E067-D5FD-469F-BAE1-3D82AC45D09DQ36669450-827D6EA8-F225-49D5-9402-0F62FF2D2D94Q36669477-66978765-55CC-4572-8D25-AF20175C0AD9Q37017315-32DC6F7A-580E-4BFB-8320-1A941CDCCA35Q37017344-64D2BD88-F84C-4167-B5E5-15EFBBA08CECQ37018920-1170D7A5-DBD5-4942-A73F-DAFD915E13A5Q37070319-FD760848-A77E-493D-9CA9-64C164A73CC9Q37101342-184E23C6-8728-4578-95E8-D8BF5A89E1FDQ37109107-E62506E2-A62E-49A0-A9F3-7823B94D98EBQ37153293-EA175241-DE1A-4326-9062-8501836EDBFEQ37224498-08F3B81D-8D63-4AD1-A9E9-7BC13469EE5EQ37253873-A68D8B20-A522-4CEF-8447-94E91BC883CC
P2860
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Disease severity and the effec ...... lmonary disease exacerbations.
@en
Disease severity and the effec ...... lmonary disease exacerbations.
@nl
type
label
Disease severity and the effec ...... lmonary disease exacerbations.
@en
Disease severity and the effec ...... lmonary disease exacerbations.
@nl
prefLabel
Disease severity and the effec ...... lmonary disease exacerbations.
@en
Disease severity and the effec ...... lmonary disease exacerbations.
@nl
P2093
P1476
Disease severity and the effec ...... lmonary disease exacerbations.
@en
P2093
Inhaled Steroids in Obstructive Lung Disease in Europe study investigators
L R Willits
P M A Calverley
P356
10.1183/09031936.03.00013303
P577
2003-01-01T00:00:00Z